Company intelligence / Profile preview

NeuroTronik

Ownership: Private
Development stage: Preclinical

Overview

Early clinical results for the NeuroTronik CANS Therapy™ System have been highly encouraging regarding safety, efficacy, and ease-of-use. The system aims to enhance cardiac output without increasing heart rate in acute heart failure patients. The company has completed Series A and B funding rounds to support development through CE Mark approval.

Therapeutic areas: Cardiovascular
Modalities: DeviceNeuromodulation therapy device
Industry: Therapeutic Medical Devices

Partnerships

Boston Scientific participated in Series B funding round but no formal partnership disclosed

Beyond the preview

Go deeper on NeuroTronik.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroTronik.

Explore the full profile